Masahiro Tohkin

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 12

Top Topics

Hodgkin Lymphoma

Top Venues

Therapeutic innovation & regulatory science

Clinical pharmacology and therapeutics

CPT: pharmacometrics & systems pharmacology

Journal of applied toxicology : JAT

This page only lists publications with an associated author ORCID identifier.

Publications

Saki Katayama, Yuka Aoki, Ayu Akita, Rino Satake, Masahiro Tohkin
Direct Comparison of the Effectiveness and Safety Among Direct Oral Anticoagulants and Warfarin in Japanese Patients: Nationwide Cohort Study in Japan. Clinical pharmacology and therapeutics (2024)
Kaori Ambe, Ayu Akita, Jie Wei, Yuka Yoshii, Mayu Onishi, Masahiro Tohkin
Comparison of Efficacy and Safety of Direct Oral Anticoagulants and Warfarin between Patients in Asian and non-Asian Regions: A Systematic Review and Meta-Regression Analysis. Clinical pharmacology and therapeutics (2023)
Takashi Watanabe, Kaori Ambe, Masahiro Tohkin
Predicting the Addition of Information Regarding Clinically Significant Adverse Drug Reactions to Japanese Drug Package Inserts Using a Machine-Learning Model. Therapeutic innovation & regulatory science 58 (2) (2023)
Kaori Ambe, Ayu Akita, Jie Wei, Yuka Yoshii, Mayu Onishi, Masahiro Tohkin
Comparison of Efficacy and Safety of Direct Oral Anticoagulants and Warfarin between Patients in Asian and Non-Asian Regions: A Systematic Review and Meta-Regression Analysis. Clinical pharmacology and therapeutics (2023)
Takashi Watanabe, Kaori Ambe, Masahiro Tohkin
Predicting the Addition of Information Regarding Clinically Significant Adverse Drug Reactions to Japanese Drug Package Inserts Using a Machine-Learning Model. Therapeutic innovation & regulatory science 58 (2) (2023)
Takashi Watanabe, Kaori Ambe, Masahiro Tohkin
Predicting the Addition of Information Regarding Clinically Significant Adverse Drug Reactions to Japanese Drug Package Inserts Using a Machine-Learning Model. Therapeutic innovation & regulatory science (2023)
Miho Murashima, Kaori Ambe, Yuka Aoki, Takahisa Kasugai, Tatsuya Tomonari, Minamo Ono, Masashi Mizuno, Masahiro Tohkin, Takayuki Hamano
Epidemiology and predictors of hyponatremia in a contemporary cohort of patients with malignancy: a retrospective cohort study. Clinical kidney journal 16 (11) (2023)
Takashi Watanabe, Kaori Ambe, Masahiro Tohkin
Predicting the Addition of Information Regarding Clinically Significant Adverse Drug Reactions to Japanese Drug Package Inserts Using a Machine-Learning Model. Therapeutic innovation & regulatory science 58 (2) (2023)
Akimasa Sanagawa, Yuji Hotta, Tomoya Kataoka, Yasuhiro Maeda, Masahiro Kondo, Yoshihiro Kawade, Yoshihiro Ogawa, Ryohei Nishikawa, Masahiro Tohkin, Kazunori Kimura
Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer medicine 7 (6) (2018)
Mitsugu Ikeda, Tatsuya Ochibe, Masahiro Tohkin
Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non-Small Cell Lung Cancer. Therapeutic innovation & regulatory science 53 (3) (2018)
Makoto Osabe, Toshiyuki Tajika, Masahiro Tohkin
Allopurinol suppresses expression of the regulatory T-cell migration factors TARC/CCL17 and MDC/CCL22 in HaCaT keratinocytes via restriction of nuclear factor-κB activation. Journal of applied toxicology : JAT 38 (2) (2017)
Takahiko Aoyama, Yoshimasa Ishida, Masato Kaneko, Aoi Miyamoto, Yoshiro Saito, Masahiro Tohkin, Shinichi Kawai, Yoshiaki Matsumoto
Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response. CPT: pharmacometrics & systems pharmacology 6 (12) (2017)